Table 1.
Baseline characteristics
| Characteristic | Treatment group | All patients | ||
|---|---|---|---|---|
| 0.5 g/kg (n = 35) | 1.0 g/kg (n = 69) | 2.0 g/kg (n = 38) | (n = 142) | |
| Female, n (%) | 13 (37.1) | 31 (44.9) | 14 (36.8) | 58 (40.8) |
| Age, years | 56 (26–73) | 59 (18–83) | 63 (30–83) | 59 (18–83) |
| Body weight, kg | 83 (56–120) | 80 (49–122) | 76 (48–122) | 79 (48–122) |
| Body mass index, kg/m2 | 27 (19–40) | 27 (17–39) | 25 (19–40) | 27 (17–40) |
| EFNS/PNS criteria, n (%) | ||||
| Definite CIDP | 35 (100) | 68 (98.6) | 38 (100) | 141 (99.3) |
| Probable CIDP | 0 | 1 (1.4) | 0 | 1 (0.7) |
| Type of CIDP, n (%) | ||||
| Typical | 34 (97.1) | 62 (89.9) | 34 (89.5) | 130 (91.5) |
| Atypical | 1 (2.9) | 7 (10.1) | 4 (10.5) | 12 (8.5) |
| Prior treatment, n (%) | ||||
| Corticosteroids | 30 (85.7) | 60 (87.0) | 34 (89.5) | 124 (87.3) |
| Immunoglobulins | 5 (14.2) | 9 (13.0) | 4 (10.5) | 18 (12.7) |
All values are the median (range) unless otherwise stated
n number of patients, CIDP chronic inflammatory demyelinating polyneuropathy, EFNS/PNS European Federation of Neurological Societies/Peripheral Nerve Society